Introduction
============

COPD is a major public health problem. In 2020, COPD is projected to rank fifth worldwide in terms of burden of disease and third in terms of mortality.[@b1-dddt-9-6379] COPD is an inflammatory disease, and lung and systemic inflammation intensifies during most COPD exacerbations.[@b2-dddt-9-6379] In COPD, repeated exposure to noxious particles, usually tobacco smoke, can trigger a distinct inflammatory cascade in the small airways and lung parenchyma involving several different cell types and inflammatory mediators.[@b3-dddt-9-6379] So, reducing oxidative stress and airway inflammation is supposed to be effective in the treatment of COPD. Those inflammatory mediators mentioned earlier have become a hot topic in the study and treatment of COPD in recent years. Many of them are defined as proinflammation cytokines but the network of those cytokines is still not very clear.[@b4-dddt-9-6379] Their role in the inflammation progress has been accepted. In the past few decades, researchers mainly focused on the development of antibodies to block the cytokine or its receptor,[@b5-dddt-9-6379]--[@b7-dddt-9-6379] and less focused on targeting intracellular signaling pathways. As a result, cytokine inhibitors have produced disappointing results in patients with COPD.[@b8-dddt-9-6379]

*N*-Acetylcysteine (NAC), an antioxidant/mucous modifier, has shown an uncertain benefit in COPD patients for decades. A number of clinical trials and system reviews have shown that NAC reduces the risk of rehospitalization for COPD and that this risk reduction maybe dose-dependent.[@b9-dddt-9-6379]--[@b12-dddt-9-6379] Several recently published reports,[@b13-dddt-9-6379]--[@b17-dddt-9-6379] using different monitors such as: inspiratory capacity, forced vital capacity (FVC), forced expiratory flow 25%--75%, and functional residual capacity, have found out that NAC can improve the lung function of COPD patients to different degrees. The traditional view of the precise way the drug works is that NAC increases intracellular reduced glutathione in the lungs and neutralizes oxidant species and also NAC is an effective mucolytic agent as it reduces sulfhydryl moieties to affect the disruption of disulfide bridges within the glycoprotein matrix of mucus.[@b18-dddt-9-6379] However, we may have underestimated the clinical utility of NAC as more recent researches suggest that NAC will affect COPD patients in many aspects from symptoms to prognosis.[@b19-dddt-9-6379] In addition, the molecular pathways of NAC are still not very clear. The different consequences of these clinical studies of NAC are partly due to the different evaluation criteria of lung function and outcomes, but we think that the different genetic backgrounds and gene polymorphism should also be taken into account. HO-1, one of the isoforms of heme oxygenase enzyme, is traditionally thought to be a fundamental "sensor" of cellular stress and directly contributes toward limiting or preventing tissue damage.[@b20-dddt-9-6379] Recent researches that focused on the signaling function of HO-1 indicate that HO-1 is a pleiotropic protein with multiple roles, including a heme degradation function leading to the formation of antioxidant bile pigments and the important signaling gas CO as well as a nonenzymatic signaling function, resulting in the regulation of gene expression, modulation of protein translation, and binding to DNA repair proteins.[@b21-dddt-9-6379] In the last couple of years, several researches have emphasized on the polymorphism of HO-1 gene and its promoter. Yamada et al[@b22-dddt-9-6379] first demonstrated that the large size of 5′-flanking polymorphism ((GT)~n~ repeat number) in the HO-1 gene was associated with chronic pulmonary emphysema susceptibility caused by cigarette smoke in Japanese patients. A similar study conducted in the Japanese population also suggests that polymorphism of the HO-1 promoter gene may be associated with the rate of decline in lung function in Japanese male ex-smokers.[@b23-dddt-9-6379] The results of a multicenter two-stage study named European Community Respiratory Health Survey suggest that a long HO-1 gene promoter, which may lead to low protein expression and activity, is associated with low lung function and accelerated lung function decline, especially in heavy smokers.[@b24-dddt-9-6379] In our previous published study,[@b25-dddt-9-6379] we provided genotyping data of HO-1 gene in southwest Chinese population and the result of the study suggested a strong association between the (GT)~n~ repeat number in the Hox-1 gene promoter and susceptible to COPD in southwest Chinese smokers. But there are still different opinions. No association was found between HO-1 (GT)~n~ alleles and the rate of decline in lung function in smokers in the north American population according to the studies conducted by Tanaka et al[@b26-dddt-9-6379] and the National Heart, Lung, and Blood Institute Lung Health Study of Canada.[@b27-dddt-9-6379] Despite the different sample size of these studies, the discrepant results also attributed to the different distribution of (GT)~n~ repeat in subjects from different population and region. We hypothesized that this polymorphism of HO-1 gene promoter could be associated with the effectiveness of oral NAC. This study was conducted to explore whether the effect of the NAC treatment would vary or not when applied to COPD patients with different length of (GT)~n~ repeat in the HO-1 gene promoter. To our knowledge, there is no related report.

Materials and methods
=====================

This study received ethics approval from the Ethics Committee of Kunming Medical University and all aspects of the experiments were performed according to the guidelines of the ethics committee. All of the patients involved in the study provided written informed consent.

Study population
----------------

Patients with COPD attending the Second Department of Respiratory of the First Affiliated Hospital of Kunming Medical University were recruited. COPD was diagnosed in accordance with Global Initiative of Obstructive Lung Disease 2011. All patients were from southwest Chinese Han population and ex-smokers since at least 1 year, with a smoking history of at least 10 pack-years, but they were clinically stable for at least 4 weeks prior to the present study. Other criteria were forced expiratory volume in 1 second/forced vital capacity (FEV~1~/FVC) \<70% and physician diagnosis of COPD with compatible symptoms, such as cough, dyspnea, etc. Patients were excluded in the following situations: a history of asthma, lung surgery, oral steroids, any other antioxidant supplements, and respiratory tract infection that needed antibiotics.

DNA genotyping
--------------

Genomic DNAs were extracted from peripheral venous blood leucocytes using the QIAamp DNA Blood Mini Kit (Qiagen NV, Venlo, the Netherlands). The (GT)~n~ repeat polymorphism was amplified by polymerase chain reaction (PCR) using the forward primer 5′-ACG CCT GGG GTG CAT CAA GTC-3′ and the reverse primer 5′-GTG GGG TGG AGA GGA GCA GTC ATA-3′, which were designed according to the published sequence in our previous study.[@b25-dddt-9-6379] PCR was performed over 30 cycles of 20 seconds at 94°C, 10 seconds at 60°C, and 20 seconds at 72°C using a fluorescently labeled deoxycytidine triphosphate (Applied Biosystems Inc., Waltham, MA, USA) as described by the manufacturer's protocol. The PCR products were electrophoresed on a denaturing polyacrylamide gel using ABI PRISM 377 sequencer (Applied Biosystems Inc.). The results were analyzed with DNASTAR.Lasergene v7.1 (DNAStar Inc., Madison, WI, USA) software package.

Study protocol
--------------

The polymorphisms of the Hox-1 gene promoter were classified into three subclasses according to the number of (GT)~n~ repeats[@b25-dddt-9-6379]: class S (\<25 (GT)~n~ repeats), class M (26--31 (GT)~n~ repeats), and class L (≥32 (GT)~n~ repeats). These subjects were then classified as having L/L, L/M, L/S, M/M, M/S, or S/S genotypes. Eligible patients were allocated to either the L+ group (patients genotyped as L/L, L/M, L/S) or the L− group (patients genotyped as M/M, M/S, S/S) based on the different genotypes of with or without L allele. Once enrolled in this research, each patient was allocated to NAC 600 mg bid (Hainan Zambon Pharmaceutical, Haikou, People's Republic of China) over a 1-year period. There were four visits: the baseline and the following time points of every 16 weeks until the end of the trial. The study design is illustrated in [Figure 1](#f1-dddt-9-6379){ref-type="fig"}.

Outcome measures
----------------

Once included, patients' basic characteristics were recorded by questionnaire. Every patient completed the Chinese version of St George's Respiratory Questionnaire (SGRQ) at each follow-up visit and meanwhile the 6-minute walking distance (6MWD) test was also conducted and recorded. Lung function testing was conducted by Cosmed Pony FX portable pulmotester (COSMED, Rome, Italy) for the following parameters: FEV~1~, FEV~1~% predicted, and FVC. The COPD exacerbation rate (per year) was defined as having the following symptoms: an increase in cough, purulence of sputum, or dyspnea, necessitating of a change in regular medication in a patient such as: using antibiotics and (or) oral corticosteroid, or hospitalizations to emergency room or a respiratory clinic. Adverse events were recorded at each study visit.

Statistical methods
-------------------

The study was designed to enroll at least a total of 340 subjects to achieve 80% power to detect the genetic association of oral NAC and COPD. The SPSS Version 21.0 (SPSS Inc., Chicago, IL, USA) software was used in the statistical analysis of this study. Data were expressed as mean ± standard deviation, unless otherwise stated.

The frequencies of Hox-1 gene promoter genotypes between different groups were compared by two-tailed chi-square test. The baseline differences of enumeration data between the two groups (such as age, smoking index, FEV~1~% predicted, and FEV~1~/FVC) were compared with unpaired *t*-test, and measurement data (such as sex) were compared with chi-square test. *P*\<0.05 was taken as statistically significant. Data in different group of each measurement time were compared pairwise with multivariate analysis of variance.

Results
=======

Study population and baseline characteristics
---------------------------------------------

Of 568 eligible patients with COPD who were screened, 94 were excluded in the run-in period: 28 subjects withdrew consent, 24 were lost to follow-up, eleven refused lung function testing or 6MWD, and 31 could not finish a receivable lung function test or 6MWD due to poor clinical condition. During the 1-year follow-up, 106 subjects out of the remaining 474 subjects dropped out the study for lost follow-up, poor compliance, or death and 368 patients completed the study ([Figure 1](#f1-dddt-9-6379){ref-type="fig"}). The baseline characteristics of the population studied are shown in [Table 1](#t1-dddt-9-6379){ref-type="table"} and there were no significant differences between groups at the baseline. The number of (GT)~n~ repeats in the HO-1 gene promoter ranged from eleven to 39. In the total population, the distribution of (GT)~n~ repeat peaks were at 22 and 30 GT repeats ([Figure 2](#f2-dddt-9-6379){ref-type="fig"}).

Follow-up visit
---------------

### Lung function test

The improvements in FEV~1~ (from 1.44±0.37 to 1.58±0.38, *P*=0.04) and FEV~1~% predicted (from 56.6±19.2 to 59.7±17.2, *P*=0.03) of the L− group were significant after the study, while there were no significant differences for changes of FEV~1~ and FEV~1~% predicted in the L+ group ([Figures 3](#f3-dddt-9-6379){ref-type="fig"} and [4](#f4-dddt-9-6379){ref-type="fig"}; [Table 2](#t2-dddt-9-6379){ref-type="table"}). There was no improvement in FVC of each group and the decline of FVC in both of the groups was not statistical significant ([Table 2](#t2-dddt-9-6379){ref-type="table"}).

#### Exacerbation rate

The total number of COPD exacerbations recorded during the 1-year follow-up was 176 (92 in L+ group and 84 in L− group). The rate of patients which had one or more COPD exacerbations of the L+ group and L− group were significantly different (40.3% vs 25.2%) (*P*=0.01) ([Figure 5](#f5-dddt-9-6379){ref-type="fig"}). The number of yearly COPD exacerbations of the L− group was 1.5±0.66, which was significantly lower than the 2.1±0.53 of the L+ group (*P*\<0.01).

#### SGRQ score and 6MWD test

The changes of SGRQ score and 6MWD test of each visit in different groups are shown in [Table 3](#t3-dddt-9-6379){ref-type="table"}. There was no significant differences in the changes of SGRQ total score (*P*=0.08), impact score (*P*=0.1), or symptom score (*P*=0.06) of the two groups after 1-year follow-up. But the change of activity score of the L− group was more significant than that of the L+ group (*P*=0.02) ([Figure 6](#f6-dddt-9-6379){ref-type="fig"}). During the 1-year follow-up, there was an improvement of the outcome of 6MWD test in both groups, but the improvement of the outcome of 6MWD test in L− group (from 290.1±44.9 to 309.7±46.9 m) was significantly higher than that in the L+ group (from 289.7±46.2 to 300.3±44.2 m) (*P*=0.03) ([Figure 7](#f7-dddt-9-6379){ref-type="fig"}).

#### Adverse effects

Twenty-three patients reported gastrointestinal complaints (eight in the L+ group and 15 in the L− group) and no other major adverse event occurred in both groups. Ten patients died during the study, including four patients in the L+ group (three from acute exacerbations of COPD, one from pneumonia) and six patients in the L− group (three from acute exacerbations of COPD, one from pneumonia, one from acute renal failure, and one from acute ischemic stroke). No deaths were regarded by investigators as related to the study products.

Discussion
==========

The present study conducted in the southwest population of the People's Republic of China showed that the use of NAC (600 mg bid for 1 year) improved the FEV~1~ and FEV~1~% predicted of COPD patients without L allele. In the study by Pela et al, a small but significant improvement in FEV~1~ and maximal expiratory flow 50 was found in COPD patients with 600 mg NAC once a day compared with COPD patients without NAC.[@b28-dddt-9-6379] However, many large, multicenter studies, such as the BRONCUS,[@b10-dddt-9-6379] PEACE,[@b29-dddt-9-6379] ECRSH,[@b24-dddt-9-6379] and PANTHEON[@b17-dddt-9-6379] which used FEV~1~ as the outcome parameter of lung function found no significant improvement of the FEV~1~ or prevention of FEV~1~ reduction rate between the NAC group and the control group. In spite of this, a subgroup analysis of the study of BRONCUS[@b10-dddt-9-6379] mentioned above showed a significant reduction in hyperinflation in COPD patients. In the study such as HIACE,[@b15-dddt-9-6379] the forced expiratory flow 25%--75% and resonance frequency, frequency dependency, and reactance and resistance at low oscillation frequency (X6 Hz and R6 Hz) were used as the outcome parameters of lung function and they found out that NAC had a beneficial role in small airway function as well as in reduction of lung hyperinflation in patients with COPD. The result of these different trials may be due to the different dose of NAC treatment and the different lung function parameters in use. In our present study, we took the gene polymorphism into account and grouped the COPD patients by the different microsatellite polymorphism in the HO-1 gene promoter and that may have attributed to the different outcome of our study.

The possible mechanism of NAC on the expression of HO-1 gene and the small airway function is still not very clear. Many in vivo and in vitro factors are involved in the pathological process of emphysema, the mucus hypersecretion as a prominent factor in airway can directly aggravate the small air trapping. As defined as a chronic inflammatory disease, the airway remodeling of COPD is strongly related to the disequilibrium of oxidation and antioxidation in airway. Both NAC and HO-1 have been mistaken for single mucus modifier or antioxidant for a long time until recent decades, the former had been proved to be not only mucous modifier, but also antioxidant. But as a classical enzyme in the redox system, there are not so many studies emphasized on the relation between HO-1 and the mucus secretion. Almolki et al[@b30-dddt-9-6379] assessed the relationship between the expression of the HO-1 and the airway mucus secretion in cigarette smoke-exposed Sprague Dawley rats and found the expression of HO-1 had a strong affection on several enzymes (EGF-R, MUC5AC, DUOX1/NADPH oxidase, TGF-α), which were involved in the airway mucus secretion pathway. A secondary analysis was also made in the same study using the data from the multicenter longitudinal European Community Respiratory Health Survey[@b24-dddt-9-6379] to evaluate the relation between HO-1 gene promoter polymorphism (the same grouping strategy of L+ and L− group as the present study) and chronic sputum prevalence in smokers. We can infer from the result of this study that HO-1 do have a significant protective effect against airway mucus hypersecretion in both Sprague Dawley rats and smokers.

Unlike the outcome of lung function, more studies drew the same conclusion on the positive effect of NAC in the prevention of COPD exacerbations. On one hand, the bacteria play a very important role in COPD exacerbations, so the hypersecretion state in the airway may stimulate the colonization of bacteria and influence the susceptibility of COPD patients to exacerbations. On the other hand, NAC as an antioxidant can increase the resistance against acute oxidative stress by providing cysteine extracellularly for the enhanced production of glutathione.[@b9-dddt-9-6379] The present study demonstrates that the 5′-flanking polymorphism in the HO-1 gene promoter is associated with the exacerbation rate of COPD patients and the exacerbation rate of COPD is much lower in the patients without the L allele. The NAC may sharpen the different expression of HO-1 in patients with different polymorphism in the HO-1 gene promoter. In consequence, the low content of HO-1 may have an adverse effect on the natural synergy of NAC and HO-1.

Although NAC may have a beneficial effect in reducing COPD exacerbations, the role of improving symptoms and quality of life is still not clear in COPD patients. In the prior BRONCUS[@b10-dddt-9-6379] trial, NAC (600 mg daily) did not improve results on the SGRQ over a 3-year period. In contrast, result of the recently published PANTHEON[@b17-dddt-9-6379] study showed that the mean SGRQ symptom scores were reduced in the NAC group compared with placebo, but did not differ in total score and other domains, which was consistent with PEACE[@b29-dddt-9-6379] study. According to the authors of those studies, different dose of NAC, sample from different ethnic origins, or the length of treatment times may be the causes of different results. The SGRQ activity score along with the result of 6MWD test were significantly improved in the L− group in our present study. But beyond all those reasons above, the different grouping method should also be taken into account.

Conclusion
==========

A 600 mg bid oral NAC treatment for 1 year has different effect in COPD patients with different genotypes. For COPD patients without the L allele, NAC can significantly improve the FEV~1~, FEV~1~% predicted, the SGRQ activity score, and the result of 6MWD test and the exacerbation rate of the L allele carrier in COPD patients is much higher than the COPD patients without the L allele. These differences could be due to the complex molecular interactions between NAC and the HO-1 or its gene promoter. A clearer understanding of these differences will allow practitioners to choose the optimal therapy in different conditions. To understand the relationship between NAC and the modification of the HO-1 expression, we still need to do more researches in COPD genetics that will integrate multiple genomic types in order to build a model to understand the complex molecular interactions involved in COPD pathogenesis.
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**Notes:** The polymorphisms of the patients' HO-1 gene promoter were classified into three subclasses according to the number of (GT)~n~ repeats, as previously reported: class S (\<27 (GT)~n~ repeats), class M (27--32 (GT)~n~ repeats), and class L (\>32 (GT)~n~ repeats). These subjects were then classified as L+ group (with the L allele: L/L, L/M, L/S) and L− group (without the L allele: M/M, M/S, S/S).\
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![The exacerbation rate of different groups.\
**Notes:** The polymorphisms of the patients' HO-1 gene promoter were classified into three subclasses according to the number of (GT)~n~ repeats, as previously reported: class S (\<27 (GT)~n~ repeats), class M (27--32 (GT)~n~ repeats), and class L (\>32 (GT)~n~ repeats). These subjects were then classified as L+ group (with the L allele: L/L, L/M, L/S) and L− group (without the L allele: M/M, M/S, S/S).\
**Abbreviation:** COPD, chronic obstructive pulmonary disease.](dddt-9-6379Fig5){#f5-dddt-9-6379}

![The changes of SGRQ activity score of different groups.\
**Notes:** The polymorphisms of the patients' HO-1 gene promoter were classified into three subclasses according to the number of (GT)~n~ repeats, as previously reported: class S (\<27 (GT)~n~ repeats), class M (27--32 (GT)~n~ repeats), and class L (\>32 (GT)~n~ repeats). These subjects were then classified as L+ group (with the L allele: L/L, L/M, L/S) and L− group (without the L allele: M/M, M/S, S/S).\
**Abbreviation:** SGRQ, St George's Respiratory Questionnaire.](dddt-9-6379Fig6){#f6-dddt-9-6379}

![The changes of 6MWD of different groups.\
**Notes:** The polymorphisms of the patients' HO-1 gene promoter were classified into three subclasses according to the number of (GT)~n~ repeats, as previously reported: class S (\<27 (GT)~n~ repeats), class M (27--32 (GT)~n~ repeats), and class L (\>32 (GT)~n~ repeats). These subjects were then classified as L+ group (with the L allele: L/L, L/M, L/S) and L− group (without the L allele: M/M, M/S, S/S).\
**Abbreviation:** 6MWD, 6-minute walking distance.](dddt-9-6379Fig7){#f7-dddt-9-6379}

###### 

Baseline characteristics of participators

  Variable                           L+ group (n=154)   L− group (n=214)   *P*-value
  ---------------------------------- ------------------ ------------------ -----------
  Age, years                         68.7±6.3           69.3±5.0           0.30
  Sex                                                                      
   Male                              140 (90.9%)        193 (90.2%)        0.42
   Female                            14 (9.1%)          21 (9.8%)          0.26
  BMI, kg/m^2^                       22.8±2.6           22.2±2.1           0.60
  Smoking status                                                           
   Smokers                           31 (20.1%)         44 (20.6%)         0.55
   Ex-smokers                        123 (79.9%)        170 (79.4%)        0.82
   Pack-years                        24.5±6.6           24.7±5.6           0.94
  Spirometry                                                               
   FEV~1~, l                         1.46±0.31          1.45±0.37          0.23
   FEV~1~% predicted                 56.4±14.8          56.6±19.2          0.71
   FVC, l                            2.3±0.2            2.4±0.4            0.12
  Exacerbations in previous 1 year   2.74±0.85          2.72±0.77          0.48
  6MWD                               289.7±16.2         290.1±14.9         0.86
  SGRQ score                                                               
   Total                             35.0±11.6          35.1±10.7          0.90
   Symptom                           40.5±10.8          40.1±12.3          0.65
   Activity                          46.7±13.9          46.2±14.5          0.22
   Impact                            25.6±10.1          26.0±11.4          0.15
  Drug use before enrollment                                               
   ICS                               9 (5.8%)           13 (6.0%)          0.09
   SABA                              71 (46.1%)         104 (48.6%)        0.78
   LABA                              4 (2.6%)           6 (2.8%)           0.57
   ICS + LABA                        77 (50.0%)         106 (49.5%)        0.39
   Theophylline                      101 (66.2%)        142 (66.4%)        0.08

**Notes:** Data are shown as number (%) or mean ± standard deviation, unless specially defined. The polymorphisms of the patients' HO-1 gene promoter were classified into three subclasses according to the number of (GT)~n~ repeats, as previously reported: class S (\<27 (GT)~n~ repeats), class M (27--32 (GT)~n~ repeats), and class L (\>32 (GT)~n~ repeats). These subjects were then classified as L+ group (with the L allele: L/L, L/M, L/S) and L− group (without the L allele: M/M, M/S, S/S).

**Abbreviations:** 6MWD, 6-minute walking distance; BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting β~2~ agonist; SABA, short-acting β~2~ agonist; SGRQ, St George's Respiratory Questionnaire.

###### 

Parameters of lung function test

  Parameter            L+ group    L− group                                   
  -------------------- ----------- ----------- ------ ----------- ----------- ------
  FEV~1~, l            1.46±0.31   1.48±0.33   0.12   1.45±0.37   1.58±0.38   0.04
  FEV~1~ % predicted   56.4±14.8   57.8±12.6   0.07   56.6±19.2   59.7±17.2   0.03
  FVC, l               2.3±0.2     2.2±0.5     0.67   2.4±0.4     2.2±0.3     0.21

**Notes:** Data are shown as mean ± standard deviation. The polymorphisms of the patients' HO-1 gene promoter were classified into three subclasses according to the number of (GT)~n~ repeats, as previously reported: class S (\<27 (GT)~n~ repeats), class M (27--32 (GT)~n~ repeats), and class L (\>32 (GT)~n~ repeats). These subjects were then classified as L+ group (with the L allele: L/L, L/M, L/S) and L− group (without the L allele: M/M, M/S, S/S).

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity.

###### 

Parameters of 6MWD test and SGRQ

  Parameter                 L+ group     L− group
  ------------------------- ------------ ------------
  **6MWD**                               
  Baseline                  289.7±16.2   290.1±14.9
  16 weeks                  291.8±12.9   293.3±18.3
  32 weeks                  295.6±18.1   299.4±10.7
  48 weeks                  300.3±14.2   309.7±16.9
  ***P*-value**             0.03         
  **SGRQ total score**                   
  Baseline                  35.0±11.6    35.1±10.7
  16 weeks                  35.7±9.6     35.9±11.3
  32 weeks                  36.2±11.2    36.4±12.4
  48 weeks                  37.4±10.4    37.8±9.0
  ***P*-value**             0.18         
  **SGRQ symptom score**                 
  Baseline                  40.5±10.8    40.1±12.3
  16 weeks                  40.8±8.4     40.8±15.1
  32 weeks                  41.1±6.9     41.6±10.3
  48 weeks                  41.7±13.7    41.6±9.7
  ***P*-value**             0.86         
  **SGRQ activity score**                
  Baseline                  46.7±13.9    46.2±14.5
  16 weeks                  46.5±14.1    46.3±11.0
  32 weeks                  46.8±8.3     46.7±12.2
  48 weeks                  46.3±11.5    47.4±15.5
  ***P*-value**             0.02         
  **SGRQ impact score**                  
  Baseline                  25.6±10.1    26.0±11.4
  16 weeks                  25.9±7.1     26.5±8.6
  32 weeks                  25.7±11.3    26.9±10.5
  48 weeks                  25.9±8.9     26.7±13.4
  ***P*-value**             0.09         

**Notes:** Data are shown as mean ± standard deviation. The polymorphisms of the patients' HO-1 gene promoter were classified into three subclasses according to the number of (GT)~n~ repeats, as previously reported: class S (\<27 (GT)~n~ repeats), class M (27--32 (GT)~n~ repeats), and class L (\>32 (GT)~n~ repeats). These subjects were then classified as L+ group (with the L allele: L/L, L/M, L/S) and L− group (without the L allele: M/M, M/S, S/S).

**Abbreviations:** 6MWD, 6-minute walking distance; SGRQ, St George's Respiratory Questionnaire.
